Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

Type 2 diabetes, linked to insulin resistance, affects a significant portion of the American population, many undiagnosed. Pre-diabetes, also caused by insulin resistance, often progresses to Type 2 ...

W hen first diagnosed with type 2 diabetes, you may have been able to manage blood sugar levels with diet, exercise, and a first-line medication. But as the condition progresses, the body becomes more ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

Diabetes has long been lumped into two categories - Type 1, which often appears in childhood, or Type 2, which is associated with obesity and typically develops later in life. But scientists have ...